NASDAQ: RPRXRoyalty Pharma PLC Stock
$55.29+0.77 (+1.41%)
Updated Jun 11, 2026
RPRX Price
$55.29
Fair Value Price
$105.23
Market Cap
$31.84B
52 Week Low
$34.08
52 Week High
$56.50
P/E
28.95x
P/B
3.2x
P/S
8.59x
PEG
0.62x
Dividend Yield
1.65%
Revenue
$2.44B
Earnings
$827.29M
Gross Margin
100%
Operating Margin
47.67%
Profit Margin
33.9%
Debt to Equity
0.99
Operating Cash Flow
$3B
Beta
0.47
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
RPRX Overview
Royalty Pharma plc, headquartered in New York City and founded in 1996, operates within the United States as a key player in the biopharmaceutical industry. The company primarily focuses on the acquisition of royalties from biopharmaceutical products and actively invests in funding new developments and innovations in the sector. Its activities involve diligently identifying, evaluating, and securing royalty agreements for a wide array of biopharmaceutical therapies. Beyond acquisitions, Royalty Pharma plc fosters collaborations with various innovators. These partners include academic institutions, research hospitals, non-profit organizations, small and mid-sized biotechnology firms, and larger pharmaceutical companies. The firm's substantial portfolio includes royalty interests in approximately 35 commercially available treatments and an additional 10 product candidates currently in different stages of development. These assets span a diverse range of critical therapeutic areas, such as rare diseases, cancer, neurological conditions, infectious diseases, hematology, and diabetes.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RPRX's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RPRX
Ranked#7 of 463
Ranked#7 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important RPRX news, forecast changes, insider trades & much more!
RPRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RPRX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RPRX ($55.29) is undervalued by 47.46% relative to our estimate of its Fair Value price of $105.23 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RPRX ($55.29) is significantly undervalued by 47.46% relative to our estimate of its Fair Value price of $105.23 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RPRX ($55.29) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more RPRX due diligence checks available for Premium users.
Valuation
RPRX fair value
Fair Value of RPRX stock based on Discounted Cash Flow (DCF)
Price
$55.29
Fair Value
$105.23
Undervalued by
47.46%
RPRX ($55.29) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RPRX ($55.29) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RPRX ($55.29) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
28.95x
Industry
17.66x
Market
13.95x
RPRX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RPRX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
RPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.2x
Industry
4.83x
RPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RPRX price to earnings growth (PEG)
For valuing profitable companies with growth potential
RPRX is good value based... subscribe to Premium to read more.
PEG Value Valuation
RPRX's financial health
Profit margin
Revenue
$630.6M
Net Income
$294.7M
Profit Margin
46.7%
RPRX's Earnings (EBIT) of $1.16B... subscribe to Premium to read more.
Interest Coverage Financials
RPRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.8B
Liabilities
$9.9B
Debt to equity
0.99
RPRX's short-term assets ($1.43B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RPRX's long-term liabilities ($9.34B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RPRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$718.2M
Investing
-$477.9M
Financing
-$272.7M
RPRX's operating cash flow ($2.61B)... subscribe to Premium to read more.
Debt Coverage Financials
RPRX vs Biotech Stocks
Royalty Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.